| Bioactivity | PI3K/HDAC-IN-3 (36) is a PI3K and HDAC dual inhibitor, with IC50 values of 0.23 nM and 172 nM for PI3Kα and HDAC1, respectively. PI3K/HDAC-IN-3 (36) suppresses AKT phosphorylation and increased H3 acetylation in MV4-11 cells. PI3K/HDAC-IN-3 (36) exhibits significant and dose-dependent anticancer efficacy in a MV4-11 xenograft model[1]. |
| Name | PI3K/HDAC-IN-3 |
| CAS | 3006905-22-9 |
| Formula | C34H34F2N6O5S |
| Molar Mass | 676.73 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kehui Zhang, et al. Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia. Eur J Med Chem. 2023 Nov 30:264:116015. |
PI3K/HDAC-IN-3
CAS: 3006905-22-9 F: C34H34F2N6O5S W: 676.73
PI3K/HDAC-IN-3 (36) is a PI3K and HDAC dual inhibitor, with IC50 values of 0.23 nM and 172 nM for PI3Kα and HDAC1, resp
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.